AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01325116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Reminder
Description: Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
Study NCT00732979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrahepatic inferior vena cava clamping
Description: The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
Study NCT00732979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No infrahepatic inferior vena cava clamping
Description: Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
Study NCT01044511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits
Description: home visits by specialist nurse 2 times and 1 phonecall
Study NCT01044511 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: hotline
Study NCT00867828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neptune Krill Oil
Description: Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
Study NCT00867828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
Study NCT00867828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (soy oil)
Description: Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
Study NCT02632240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery:The tunnel technique for covering gingival recession
Description: The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
Study NCT02916394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-ZIGF-1R:4：40
Description: No Intervention
Study NCT02066818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Study NCT02066818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine
Study NCT02706886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
Study NCT02706886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
Study NCT04420585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
Study NCT01529541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagliptin
Description: Anagliptin 100mg, tablet, twice a day (BID)
Study NCT01655849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: z160
Study NCT01655849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02491372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
Study NCT03871738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes.
Study NCT02673801 — intervention group
Intervention type: OTHER
Intervention: Orthopedic assessment in the outpatient clinic
Description: Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
Study NCT03673345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
Study NCT03846115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Seeking Safety app
Description: This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
Study NCT03846115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control app
Description: This app offers the Seeking Safety content but without the enhanced features
Study NCT02631460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 80-120 mg/d
Description: d1, every 3 weeks
Study NCT02631460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed 500 mg/m2
Description: d1, every 3 weeks
Study NCT02631460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin AUC=5
Description: d1, every 3 weeks
Study NCT02631460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin AUC=5
Description: d1, every 3 weeks
Study NCT01746498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct current stimulation using Anodal electrode
Description: 11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
Study NCT01746498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct current stimulation using cathodal electrode
Description: 11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
Study NCT01746498 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham direct current stimulation
Description: 11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
Study NCT01665846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
Study NCT03051698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-inhibitor
Description: 100 Unit/kg IV, one gift prior to broncho provocation.
Study NCT03051698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl
Study NCT03051698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: vancomycin, ciprofloxacin, metronidazole
Study NCT02317835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DFUPS
Description: The DFUPS device is a two-camera instrument for capturing images of feet
Study NCT04145375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: Up to 120mg
Study NCT04145375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg
Study NCT03542331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
Study NCT03542331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mock catheter
Description: Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
Study NCT04058106 — intervention group
Intervention type: PROCEDURE
Intervention: A patient who need the cerebral artery aneurysm clipping surgery
Description: A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
Study NCT03270475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: subjects complete 4-5 weeks of training
Study NCT02035748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: 0.5 mg/0.2 mL solution for injection
Study NCT01115556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 2.0 mg
Study NCT01115556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg
Study NCT01944618 — intervention group
Intervention type: DRUG
Intervention: Forxiga
Description: FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
Study NCT03794102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
Study NCT03794102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
Study NCT02319967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPE
Description: Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
Study NCT02319967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW home visits
Description: Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
Study NCT02824016 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biological sample
Description: T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
Study NCT02824016 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular irradiation
Description: Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
Study NCT00655473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (RO4607381)
Description: 600mg po daily for 24 months
Study NCT00655473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 24 months
Study NCT03958214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipe 4 Success
Description: Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
Study NCT03958214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice Early Head Start
Description: Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
Study NCT04144036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neihulizumab, 3 mg/kg
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Study NCT04144036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neihulizumab, 6 mg/kg
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Study NCT04144036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neihulizumab, 9 mg/kg
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Study NCT04144036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neihulizumab
Description: This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
Study NCT00196339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 5
Description: Cyproterone acetate 5 mg
Study NCT00196339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00196339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 15
Description: Cyproterone acetate 15 mg
Study NCT00196339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 25
Description: Cyproterone acetate 25 mg
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General condition
Description: Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General condition
Description: Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood pressure
Description: systolic blood pressure (SBP)/diastolic blood pressure (DBP)
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure
Description: systolic blood pressure (SBP)/diastolic blood pressure (DBP)
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient Reported Outcome
Description: Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Reported Outcome
Description: Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical findings
Description: * Blood and lymphatic system disorders: febrile neutropenia~* Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~* General disorders and administration site conditions: fatigue and malaise~* Immune system disorders: allergic reaction~* Metabolism and nutrition disorders: anorexia~* Nervous system disorders: dysgeusia and peripheral sensory neuropathy~* Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~* Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~* Vascular disorders: hypertension~* Symptomatic pancreatitis
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical findings
Description: * Blood and lymphatic system disorders: febrile neutropenia~* Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~* General disorders and administration site conditions: fatigue and malaise~* Immune system disorders: allergic reaction~* Metabolism and nutrition disorders: anorexia~* Nervous system disorders: dysgeusia and peripheral sensory neuropathy~* Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~* Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~* Vascular disorders: hypertension~* Symptomatic pancreatitis
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hematology/blood chemistry
Description: White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hematology/blood chemistry
Description: White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coagulation and fibrinolysis system
Description: international normalized ratio (INR)
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coagulation and fibrinolysis system
Description: international normalized ratio (INR)
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urinalysis
Description: Proteinuria (qualitative)
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinalysis
Description: Proteinuria (qualitative)
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medication check
Description: Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication check
Description: Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adverse event
Description: CTCAE ver.4.0
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse event
Description: CTCAE ver.4.0
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thyroid function test
Description: Thyroid-stimulating hormone (TSH), T4, and T3
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid function test
Description: Thyroid-stimulating hormone (TSH), T4, and T3
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Contrast-enhanced torso CT
Description: It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced torso CT
Description: It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brain MRI
Description: If any symptom of brain metastasis is suspected
Study NCT02288078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: If any symptom of brain metastasis is suspected
Study NCT02288078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Capsule filled with dexamethasone and lactose
Study NCT02288078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regorafenib
Description: Film-coating tablet contains 40 mg of regorafenib
Study NCT02288078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Film-coating tablet contains 40 mg of regorafenib
Study NCT02288078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule filled with lactose